Tag: Cell death

Overexpression of anti-apoptotic Bcl-2 family proteins is a hallmark of many cancers, making them an attractive target for novel therapies. The investigational anti-cancer agent Obatoclax is a BH3 mimetic designed to inhibit these pro-survival proteins. So, what is the mechanism of action of Obatoclax? Its effects are multifaceted and extend beyond simple apoptosis inhibition.

While many antibiotics that inhibit bacterial protein synthesis are only bacteriostatic, simply halting growth, aminoglycosides have a uniquely lethal mechanism. This article explores the cascade of synergistic and irreversible events that explains **why are aminoglycosides bactericidal and not bacteriostatic**.

Gendicine was the first commercial gene therapy product for cancer approved globally by the Chinese State Food and Drug Administration in 2003. The therapy, often known as recombinant adenovirus p53 or rAd-p53, targets malignant cells by delivering a functional copy of the critical p53 tumor-suppressor gene.